wire - news in brief


Category


Years
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008

Last News


Results 201 - 250 of 300.

Administration/Government
15.12.2016
Physics/Materials Science
15.12.2016
The All-In-One outdoor sleep system for
The All-In-One outdoor sleep system for
As of today the All-In-One sleep system developed by the «Polarmond» start-up company is ready for delivery.
Medicine/Pharmacology - Life Sciences
15.12.2016
Magnetic forces purify the blood
Magnetic forces purify the blood
Every five seconds, someone in the world dies from blood poisoning. Hemotune, a young start-up founded by ETH researchers, is developing a revolutionary blood purification system to address this problem. Lukas Langenegger picks up a small glass ampoule containing a dark, reddish-brown fluid. Then he holds a magnet against the vial, and iron particles accumulate on the edge of the glass as if by magic, leaving behind a crystal-clear fluid.
Environment/Sustainable Development - Earth Sciences
14.12.2016
The open-air researcher
The open-air researcher
Atmospheric scientist Julia Schmale is starting out, together with more than fifty other researchers, on a three-month research cruise around the Antarctic.
Administration/Government - Careers/Employment
14.12.2016
A record for EPFL's startups: close to CHF 400 million raised in 2016
A record for EPFL's startups: close to CHF 400 million raised in 2016
Start-ups linked to EPFL raised almost CHF 400 million this year - that's over 50% more than in 2014, the last record year.
Physics/Materials Science
13.12.2016
A golden era for
A golden era for "fashionistas"
The gold thread developed at Empa is having extensive repercussions. Hot on the heels of a dessous collection being refined with the new technology, scarves and luxury watches are now also available.
Chemistry - Physics/Materials Science
12.12.2016
In the focus of the protons
In the focus of the protons
In several laboratories at the Paul Scherrer Institute PSI, researchers work with radioactive substances that eventually should aid in the diagnosis and treatment of cancer or metabolic diseases - bu
Medicine/Pharmacology
12.12.2016
Novartis provides update on pegpleranib Phase III clinical trial program in patients with neovascular age-related macular degeneration (nAMD or wet AMD)
Novartis provides update on pegpleranib Phase III clinical trial program in patients with neovascular age-related macular degeneration (nAMD or wet AMD) Two pivotal Phase III studies did not show additional improvement in best corrected visual acuity (BCVA) for pegpleranib and Lucentis (ranibizumab) combination treatment over standard of care Lucentis monotherapy , Recent Lucentis EU approval in new choroidal neovascularization (CNV)  indication
Medicine/Pharmacology - Administration/Government
12.12.2016
Novartis launches SMS for Life 2.0 in Nigeria to help improve access to essential medicines
SMS for Life 2.0 launches for the first time in Kaduna State, Nigeria's third most populous region, in collaboration with the Kaduna State Ministry of Health   Program uses smartphones and tablet
Medicine/Pharmacology
12.12.2016
EPFL spinoff QGel raises 12 million dollars from private investors
EPFL spinoff QGel raises 12 million dollars from private investors
QGel is a startup that makes a synthetic gel for growing cells as if they were in the human body. This breakthrough enhances the reliability of research into anti-cancer drugs.
Physics/Materials Science
09.12.2016
Eight professors appointed at ETH Zurich
Eight professors appointed at ETH Zurich
Upon application of ETH President Lino Guzzella the ETH Board appointed a total of eight professors and awarded the title of professor to one individual.
Medicine/Pharmacology
09.12.2016
Novartis LEE011 (ribociclib) plus letrozole analyses show superior PFS across broad spectrum of patients in first-line HR+/HER2- advanced breast cancer versus letrozole
Novartis LEE011 (ribociclib) plus letrozole analyses show superior PFS across broad spectrum of patients in first-line HR+/HER2- advanced breast cancer versus letrozole MONALEESA-2 analyses demonstrate superior PFS with LEE011 plus letrozole in pre-defined patient subgroups - from de novo to bone, liver and lung metastases - compared to letrozole alone   LEE011 plus letrozole reduced risk of progression or death by 55% over letrozole alone in de
Business/Economics - Careers/Employment
09.12.2016
Medicine/Pharmacology - Event
08.12.2016
The R. Geigy Foundation honours efforts to overcome ’neglected tropical diseases
Giovanna Raso and Jean Coulibaly are the awardees of the R. Geigy-Award 2016 and will share a CHF 20,000 prize in honour of their efforts to fight neglected helminth infections in West Africa.
Chemistry
08.12.2016
Space age material for the masses
Space age material for the masses
Aerogel is the perfect material for many insulation purposes. It is heat-resistant up to 600 degrees, ultralight, non-toxic - and provides excellent thermal insulation.
Medicine/Pharmacology
08.12.2016
Back to life
«A few months after the proton treatment was over, I realised that I could see more and more. Just dimly, it's true, but I could see! That was sensational!» More than a year ago, Gabi Meier* was treated with proton therapy at the Paul Scherrer Institute PSI.
Mechanical Engineering/Mechanics - Politics
08.12.2016
The mechanical clock of the 21st century on display in Neuchâtel
The mechanical clock of the 21st century on display in Neuchâtel
A highly innovative mechanical clock invented, designed and set in motion by EPFL will soon be installed in the Neuchâtel city hall.
Medicine/Pharmacology
08.12.2016
Novartis’ Ultibro Breezhaler improved lung function and COPD symptoms after direct switch from previous treatment
Ultibro Breezhaler improved lung function and breathlessness after direct switch from long-acting bronchodilators or steroid-containing combination therapies   Results further support the 2017 GOLD recommendations that dual bronchodilation should be the foundation treatment for the majority of symptomatic COPD patients   Data from the pragmatic CRYSTAL study showcased for the first time at the 2016 British Thoracic Society Winter Meeting in Lond
Administration/Government - Event
07.12.2016
Medicine/Pharmacology - Life Sciences
07.12.2016
Roche’s Avastin (bevacizumab) plus chemotherapy receives FDA approval for platinum-sensitive recurrent ovarian cancer
Roche's Avastin (bevacizumab) plus chemotherapy receives FDA approval for platinum-sensitive recurrent ovarian cancer Approval based on two large Phase III studies including GOG-0213 that showed a five month overall survival difference for women with platinum-sensitive recurrent ovarian cancer on Avastin plus chemotherapy compared to chemotherapy alone In the United States, Avastin is now approved for nine distinct uses across six different type
Medicine/Pharmacology - Life Sciences
07.12.2016
Novartis’ Lucentis received EU approval in new indication - Lucentis the only treatment available for a wide range of CNV conditions
Novartis' Lucentis received EU approval in new indication - Lucentis the only treatment available for a wide range of CNV conditions The European Commission approved Lucentis to treat patients for vi
Medicine/Pharmacology
07.12.2016
Virtual Reality in Medicine: New Opportunities for Diagnostics and Surgical Planning
Virtual Reality in Medicine: New Opportunities for Diagnostics and Surgical Planning
Before an operation, surgeons have to obtain the most precise image possible of the anatomical structures of the part of the body undergoing surgery.
Environment/Sustainable Development - Medicine/Pharmacology
06.12.2016
Phase two of EPFL's expansion in Valais
Phase two of EPFL's expansion in Valais
Patrick Aebischer and Valais State Councilor Esther Waeber-Kalbermatten signing the agreement, in presence of Martin Vetterli and Jean-Michel Cina.
Medicine/Pharmacology - Life Sciences
06.12.2016
Novartis announces Zykadia first-line study results showing 16.6 month progression-free survival in patients with ALK+ advanced NSCLC
Patients without brain metastases at diagnosis experienced median progression-free survival of 26.3 months, the longest seen in a global Phase III study in ALK+ NSCLC   Patients with measurable brain metastases in the Zykadia arm experienced an intracranial response rate of more than 70%   Data will be used to support global regulatory submissions for first-line use of Zykadia in ALK+ advanced NSCLC patients - Novartis today announced result
Physics/Materials Science - Chemistry
06.12.2016
Brilliance in cutting-edge research
Brilliance in cutting-edge research
Switzerland's credentials as a research location have been enhanced with a major new facility: the SwissFEL X-ray free-electron laser was put into operation at the PSI yesterday. ETH researchers are among those expecting to use the system to gain insights into hitherto hidden processes at the molecular and atomic level.
Medicine/Pharmacology - Life Sciences
05.12.2016
New interim data demonstrate Sandoz proposed biosimilar rituximab has equivalent efficacy to reference product
ASSIST-FL trial demonstrates equivalent safety, efficacy, pharmacokinetics and pharmacodynamics of Sandoz proposed biosimilar rituximab (GP2013) to the reference product Interim data in over 600 adults show potential of GP2013 as an alternative rituximab Sandoz proposed biosimilar rituximab is the company's first monoclonal antibody candidate Holzkirchen, December 5, 2016 - Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today announced data from the ASSIST-FL trial.
Medicine/Pharmacology
05.12.2016
Novartis survey uncovers real-world burden of myeloproliferative neoplasms (rare blood cancers) on daily activity and ability to work
Findings across six countries and four continents showed a reduction in quality of life for majority (71%) of patients living with myeloproliferative neoplasms (MPNs)     Patients reported a diminished capacity of more than 35% when trying to work, highlighting reduction in quality of life can extend to the workplace   First international survey of 699 patients with an MPN, specifically myelofibrosis, polycythemia vera or essential thrombocythem
Medicine/Pharmacology - Chemistry
05.12.2016
Novartis data shows Treatment-free Remission rates are consistently above 50% regardless of reason for switch to Tasigna from Glivec
ENESTop post-hoc analysis provides further insights into Treatment-free Remission (TFR) among Ph+ CML switch patients The Tasigna TFR trials, including ENESTop, demonstrate our continued commitment to the CML community - Novartis today announced at the 58th American Society of Hematology (ASH) Annual Meeting & Exposition new data from the Tasigna (nilotinib) ENESTop Treatment-free Remission (TFR) study, which demonstrate that TFR rates are c
Medicine/Pharmacology - Life Sciences
05.12.2016
Re-emergence of Syphilis Traced to Pandemic Strain Cluster
Re-emergence of Syphilis Traced to Pandemic Strain Cluster
Syphilis has plagued humankind for over 500 years. After the first reported outbreaks struck Europe in 1495, the disease spread rapidly to other continents and swelled to a global pandemic. When treatment with the antibiotic penicillin became available in the mid-twentieth century, infection rates started to decrease dramatically.
Architecture
05.12.2016
An innovative window system earns a European patent
An innovative window system earns a European patent
A window-glazing system developed by an EPFL team uses micro-mirrors to improve the lighting and visual comfort inside buildings and could also make window blinds obsolete one day.
Life Sciences - Medicine/Pharmacology
05.12.2016
Researchers uncover protein-based ‘cancer signature'
Researchers uncover protein-based ‘cancer signature’
A research team at the University of Basel's Biozentrum has investigated the expression of ribosomal proteins in a wide range of human tissues including tumors and discovered a cancer type specific signature. As the researchers report in ‘Genome Biology' this ‘cancer signature' could potentially be used to predict the progression of the disease.
Event - Administration/Government
05.12.2016
SwissFEL inauguration
SwissFEL inauguration
Today, on 5 December 2016, the Paul Scherrer Institute PSI held an inauguration ceremony for its new large-scale research facility Swiss FEL, with Johann N. Schneider-Ammann, President of the Swiss Confederation, in attendance.
Medicine/Pharmacology - Physics/Materials Science
05.12.2016
Roche’s Gazyva/Gazyvaro Helped People With Previously Untreated Follicular Lymphoma Live Significantly Longer Without Their Disease Worsening Compared to MabThera/Rituxan
Roche's Gazyva/Gazyvaro Helped People With Previously Untreated Follicular Lymphoma Live Significantly Longer Without Their Disease Worsening Compared to MabThera/Rituxan First Phase III study to show superior progression-free survival compared to MabThera/Rituxan-based standard of care treatment for most common slow-growing form of non-Hodgkin lymphoma Results were presented during the Plenary Scientific Session at 58th American Society of Hema
Medicine/Pharmacology - Life Sciences
04.12.2016
Novartis presents results from first global registration trial of CTL019 in pediatric and young adult patients with r/r B-ALL
82% (41 of 50) of patients achieved complete remission or complete remission with incomplete blood count recovery in interim analysis of Novartis study (ELIANA) ELIANA, the first global CAR T'cell tr
Medicine/Pharmacology
03.12.2016
Novartis SEG101 (crizanlizumab, formerly SelG1) significantly reduces frequency of sickle cell pain crises in Phase II study
SEG101 reduced annual rate of sickle cell-related pain crises (SCPC) by 45.3% compared to placebo in patients with or without hydroxyurea therapy   SEG101 is a potential new disease-modifying, preventive treatment option for patients with SCPC; first in nearly 20 years   Data being highlighted in ASH 2016 media briefing, presented at Plenary Scientific Session and published simultaneously in The New England Journal of Medicine Basel, Decembe
Astronomy - Environment/Sustainable Development
02.12.2016
European Space Agency’s ESA successful Ministerial Council meeting in Switzerland
Bern, 02.12.2016 - The Ministers responsible for space affairs from ESA Member States came together on 1-2 December 2016 to make important decisions, namely on the strategy to ensure Europe r
Life Sciences - Media
02.12.2016
Evaluation of scientific rigor in animal research
Media releases, information for representatives of the media Media Relations (E) In the course of the ‘reproducibility crisis' in biomedical research, scientific rigor in animal reserach, and thus the ethical justification of animal experiments, has also been questioned. Commissioned by the Swiss Federal Food Safety and Veterinary Office (FSVO), researchers from the University of Bern have assessed scientific rigor in animal experimentation in Switzerland.
Chemistry - Physics/Materials Science
02.12.2016
EPFL installs world-unique NMR system
EPFL installs world-unique NMR system
EPFL's Institute of Chemical Sciences and Engineering (ISIC) has installed an NMR system with the highest sensitivity and resolution in the world.
Business/Economics - Astronomy
01.12.2016
President Schneider-Ammann attends ESA Ministerial Council
Bern, 01.12.2016 - On 1 December, President Johann N. Schneider-Ammann addressed the ministers of the 22 member states of the European Space Agency ESA and Canada in Lucerne.
Business/Economics - Computer Science/Telecom
01.12.2016
Swiss businesses are good process innovators
Swiss businesses are good process innovators
Switzerland's economy is facing some tough challenges: technologies are developing rapidly, processes are being amalgamated both inside and outside production facilities, and business units are becoming increasingly interconnected.
Physics/Materials Science
01.12.2016
Researchers Take First Look into the ‘Eye' of Majoranas
Researchers Take First Look into the ‘Eye’ of Majoranas
Majorana fermions are particles that could potentially be used as information units for a quantum computer. An experiment by physicists at the Swiss Nanoscience Institute and the University of Basel's Department of Physics has confirmed their theory that Majorana fermions can be generated and measured on a superconductor at the end of wires made from single iron atoms.
Medicine/Pharmacology
30.11.2016
World Aids Day 2016: Hands Up for #HIVprevention
Over the past 35 years the global impact of HIV has changed the course of history. In spite of progress in access to testing and treatment in the last decade, inadequate investment in prevention means that some of the most vulnerable people remain at risk.
Physics/Materials Science - Mechanical Engineering/Mechanics
29.11.2016
Gaming in the name of science
Gaming in the name of science
Quantum mechanics can be entertaining: anyone with a few minutes to spare for a video game on 30 November can do their bit to help solve a fundamental question of physics that was once argued over by Albert Einstein and Nils Bohr. ETH Professor Andreas Wallraff explains what the Big Bell Test is all about.
Environment/Sustainable Development - Architecture
29.11.2016
Reconciling solar energy and heritage preservation
Reconciling solar energy and heritage preservation
Maria Cristina Munari Probst created a database of examples of solar panels that either fit or do not fit harmoniously in their urban setting.
Careers/Employment
29.11.2016
Employment barometer in 3rd quarter 2016: Employment growth slows
Neuchâtel, 29.11.2016 (FSO) - In the 3rd quarter 2016, total employment (number of jobs) rose by 0.3% in comparison with the same quarter a year earlier (-0.1% compared with the previous quarter).
Medicine/Pharmacology - Business/Economics
29.11.2016
Novartis Access shares one-year learnings and announces memorandum of understanding with Rwanda
Rwanda becomes third country to launch Novartis Access portfolio against chronic diseases with first deliveries planned in early 2017 Since September 2015, Novartis Access has delivered more than 100
Medicine/Pharmacology - Life Sciences
28.11.2016
Successfully Treating Genetically Determined Autoimmune Enteritis
Using targeted immunotherapy, doctors have succeeded in curing a type of autoimmune enteritis caused by a recently discovered genetic mutation. This report comes from researchers at the Department of Biomedicine of the University of Basel and University Hospital Basel. Their results raise new possibilities for the management of diarrhea, which is often a side effect of melanoma treatment.